Search | Clinical Trials Finder

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis, Acute Chest Syndrome
Interventions: A-001, Placebo; Drug · Other
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 5 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Anemia, Sickle Cell
Interventions: Rivipansel, Placebo; Drug · Other
Lead sponsor: Biossil Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 126
States / cities: Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more

Conditions: Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions: Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen; Drug · Other
Lead sponsor: St. Louis University; Other
Eligibility: 5 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Vaso-occlusive Crisis, Sickle Cell Anemia Crisis
Interventions: hyperbaric oxygen therapy; Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Anemia, Sickle Cell, Pain
Interventions: Fentanyl Citrate, Normal Saline; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Sickle Cell Disease
Interventions: Crovalimab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Sickle Cell Disease, Sickle Cell Crisis
Interventions: Ketamine hydrochloride injection, Placebo; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 24 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Etavopivat tablets; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: Cerritos, California • Los Angeles, California • Oakland, California + 9 more

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Patient controlled analgesia, nurse-administered intermittent IV bolus opioid therapy (NAIBOD); Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sickle Cell Crisis, Sickle Cell Disease
Interventions: Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease
Interventions: Hydromorphone (Standardized, weight-based dosing), Morphine Sulfate (Standardized, weight-based dosing), Hydromorphone (Patient Specific dosing), Morphine Sulfate (Patient Specific dosing); Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Sickle Cell Disease
Interventions: Anumigilimab, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Little Rock, Arkansas • Orange, California • Hollywood, Florida + 6 more

Conditions: Sickle Cell Disease
Interventions: SelG1, Placebo; Drug
Lead sponsor: Reprixys Pharmaceutical Corporation; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 49
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more

Conditions: Sickle Cell Disease
Interventions: Electronic Diary; Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Hollywood, Florida • Upper Marlboro, Maryland • Waltham, Massachusetts + 1 more

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Sickle Cell Disease
Interventions: MST-188; Drug
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 9
States / cities: San Diego, California • Fort Myers, Florida • Hollywood, Florida + 6 more

Conditions: Sickle Cell Disease Vaso-occlusive Crisis
Interventions: CSL889, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Oakland, California • Orange, California • Fort Myers, Florida + 14 more

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Suvankar Majumdar; Other
Eligibility: 4 Years to 21 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Placebo, Dalteparin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hemoglobin SC Disease
Interventions: Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid; Drug · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more

Conditions: Sickle Cell Anemia
Interventions: L-NMMA, Sodium Nitrite; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease (SCD)
Interventions: crizanlizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 12
States / cities: Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions: Inclacumab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more

Conditions: Sickle Cell Disease
Interventions: Crizanlizumab, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 13 more

Search by objective public record fields.

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

Hyperbaric Oxygen Therapy in Sickle Cell Pain

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

Optimal Timing of Ketamine Initiation for SCD Pain

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)

Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease

Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

A Study to Learn About Sickle Cell Disease In Adult Patients

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Evaluation of Repeat Administration of Purified Poloxamer 188

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)